NasdaqGS:OLMABiotechs
Why Olema Pharmaceuticals (OLMA) Is Down 7.1% After Bayer OP-3136 Prostate Cancer Trial Deal And Data
In May 2026, Olema Pharmaceuticals announced preliminary Phase 1 data showing its KAT6 inhibitor OP-3136 was generally well-tolerated with early signs of anti-tumor activity, and entered a clinical trial collaboration and supply agreement with Bayer to test OP-3136 plus NUBEQA in metastatic castration-resistant prostate cancer.
The collaboration allows Olema to jointly own combination data with Bayer while retaining full global commercial and marketing rights to OP-3136, an unusual balance...